Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in japanese patients with esophageal squamous cell carcinoma

International Journal of Medical Sciences

Volumn 11, Issue 4, 2014, Pages 321-326

  Minegaki, Tetsuya ^a   Kuwahara, Akiko ^b,c   Yamamori, Motohiro ^b,c   Nakamura, Tsutomu ^b   Okuno, Tatsuya ^b   Miki, Ikuya ^b   Omatsu, Hideaki ^b   Tamura, Takao ^b,d   Hirai, Midori ^b   Azuma, Takeshi ^b   Sakaeda, Toshiyuki ^b,e   Nishiguchi, Kohshi ^a,b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^d KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

Biomarker; Chemoradiotherapy; Esophageal squamous cell carcinoma; Polymorphism; SLC23A2

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; CHEILITIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENOTYPE; HUMAN; JAPANESE; LEUKOPENIA; LONG TERM SURVIVAL; MALE; MIDDLE AGED; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SLC23A2 GENE; STOMATITIS;

BIOMARKER; CHEMORADIOTHERAPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; POLYMORPHISM.; SLC23A2;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SODIUM-COUPLED VITAMIN C TRANSPORTERS; TREATMENT OUTCOME;

EID: 84896695077     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.7654     Document Type: Article

References (32)

1. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999; 17: 2915-2921.
2. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003; 88: 18-24.
3. Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005; 35: 316-323.
4. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003; 21: 2697-2702.
5. Kumekawa Y, Kaneko K, Ito H, et al. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol. 2006; 41: 425-432.
6. Miki I, Tamura T, Nakamura T, et al. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit. 2005; 27: 369-374.
7. Okuno T, Tamura T, Yamamori M, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol. 2007; 30: 252-257.
8. Sakaeda T, Yamamori M, Kuwahara A, et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit. 2008; 30: 497-503.
9. Kuwahara A, Yamamori M, Fujita M, et al. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2010; 29: 100.
10. Miki I, Nakamura T, Kuwahara A, et al. THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma. Int J Med Sci. 2012; 9: 748-756.
11. Kuwahara A, Yamamori M, Kadoyama K, et al. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2011; 30: 94.
12. Tamura T, Kuwahara A, Yamamori M, et al. VEGF-634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci. 2012; 9: 833-837.
13. Kryston TB, Georgiev AB, Pissis P, et al. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011; 711: 193-201.
14. Byers T, Guerrero N. Epidemiologic evidence for vitamin C and vitamin E in cancer prevention. Am J Clin Nutr. 1995; 62: 1385S-1392S.
15. Tsukaguchi H, Tokui T, Mackenzie B, et al. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999; 399: 70-75.
16. Mandl J, Szarka A, Bánhegyi G. Vitamin C: update on physiology and pharmacology. Br J Pharmacol. 2009; 157: 1097-1110.
17. Savini I, Rossi A, Pierro C, et al. SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids. 2008; 34: 347-355.
18. Savini I, Rossi A, Catani MV, et al. Redox regulation of vitamin C transporter SVCT2 in C2C12 myotubes. Biochem Biophys Res Commun. 2007; 361: 385-390.
19. Skibola CF, Bracci PM, Halperin E, et al. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS One. 2008; 3: e2816.
20. Chen AA, Marsit CJ, Christensen BC, et al. Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer. Carcinogenesis. 2009; 30: 977-981.
21. Erichsen HC, Peters U, Eck P, et al. Genetic variation in sodium-dependent vitamin C transporters SLC23A1 and SLC23A2 and risk of advanced colorectal adenoma. Nutr Cancer. 2008; 60: 652-659.
22. Wright ME, Andreotti G, Lissowska J, et al. Genetic variation in sodium-dependent ascorbic acid transporters and risk of gastric cancer in Poland. Eur J Cancer. 2009; 45: 1824-1830.
23. Abdel-Latif MM, Raouf AA, Sabra K, et al. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother. 2005; 17: 539-549.
24. Karasawa H, Miura K, Fujibuchi W, et al. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci. 2009; 100: 903-913.
25. Minegaki T, Takara K, Hamaguchi R, et al. Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett. 2013; 5: 427-434.
26. Doroshow JH. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst. 2006; 98: 223-225.
27. Numazawa S, Sugihara K, Miyake S, et al. Possible involvement of oxidative stress in 5-fluorouracil-mediated myelosuppression in mice. Basic Clin Pharmacol Toxicol. 2011; 108: 40-45.
28. García-de-la-Asunción J, Gómez-Cambronero LG, Del Olmo ML, et al. Vitamins C and E prevent AZT-induced leukopenia and loss of cellularity in bone marrow. Studies in mice. Free Radic Res. 2007; 41: 330-334.
29. de la Asunción JG, del Olmo ML, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest. 1998; 102: 4-9.
30. de la Asunción JG, del Olmo ML, Sastre J, et al. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology. 1999; 29: 985-987.
31. de la Asunción JG, Del Olmo ML, Gómez-Cambronero LG, et al. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci. 2004; 76: 47-56.
32. Eck P, Erichsen HC, Taylor JG, et al. Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. Hum Genet. 2004; 115: 285-294.